secwatch.observer — SEC 8-K summary
======================================

Issuer:     Altimmune, Inc. (ALT)
CIK:        0001326190
Form:       8-K
Filed at:   2025-12-19T23:59:59+00:00
Accession:  0001104659-25-122724
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Altimmune reports positive 48-week IMPACT data; FDA agrees on Phase 3 path for pemvidutide
--------------------------------------------------------------------------------

- Pemvidutide 1.8 mg reduced ELF by -0.58 (p<0.0001) and LSM by -3.97 (p<0.001) vs placebo at 48 weeks.
- Weight loss of 7.5% (1.8 mg, p<0.0001) vs 0.2% placebo; no plateau at 48 weeks; AE discontinuation 1.2% vs 3.5%.
- Proportion achieving both ELF ≥0.5 reduction and LSM ≥30% reduction: 32.4% (1.8 mg) vs 3.2% placebo (p<0.0001).
- End-of-Phase 2 FDA meeting on Dec 11 aligned on Phase 3 design; FDA open to AIM-MASH AI tool; plan to evaluate 2.4 mg dose.
- Altimmune raised ~$54.6M net from ATM sales of 13.5M shares after Sep 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326190/000110465925122724/0001104659-25-122724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326190/000110465925122724/tm2533869d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-122724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer